2015 年第 2 期 第 13 卷

贝伐珠单抗联合化疗治疗4例晚期持续/或复发性子宫肉瘤的临床疗效分析

作者：

单位：

关键词：子宫肉瘤贝伐珠单抗联合化疗

• 摘要：
• 【摘要】目的：观察贝伐珠单抗（bevacizumab,BEV）联合化疗治疗晚期持续/或复发性子宫肉瘤的临床疗效。方法：对我院自2006年5月至2014年5月采用贝伐珠单抗与化疗联合治疗的4例晚期持续或复发性子宫肉瘤患者的临床资料进行回顾性分析，评价治疗的有效率（CR+PR）、临床获益率（CR+PR+SD）、无进展生存期（PFS和总生存期(OR), 并评价其安全性和毒性反应。结果：4例患者中，1例达CR，无瘤生存时间为96个月；1例达PR，无进展生存期为13个月，总生存时间为25个月；1例为SD, 无进展生存期为9个月，总生存时间为24个月；1例为PD, 无进展生存期为3个月，总生存时间为9个月。治疗有效率（CR+PR）为50％（2/4），临床获益率75%（3/4）。总的平均PFS 30.25个月，平均OS 38.5个月。 4例患者发生与治疗相关的毒副反应主要是骨髓抑制和胃肠道反应。其中1例患者为 IV度血液性毒性（PLT减少），余3例为II度骨髓抑制（WBC减少）；非血液学毒性主要是胃肠道反应（恶心、呕吐），其中2例患者为II度，2例为I度。结论：BEV联合化疗可有效控制晚期或复发性子宫肉瘤,且耐受性好，可能是治疗晚期或复发性子宫肉瘤安全、有效的候选方案。
• The curative effect observation of 4 advanced or recurrent patients with uterine sarcoma using Bevacizumab combined with chemotherapy Han Ying, Li Shu-min , Bai Ping ,Zhang Rong. Peking Union Medical College, Department of Gynecologic Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing,100021,China Corresponding author: Li Shu-min, Email: lotus-2013@qq.com [Abstract] objective: To observe the clinical effect of BEV combining chemotherapy in advanced or recurrent uterine sarcomas. Method : Retrospectively analyzed clinical data of 4 advanced or recurrence refractory uterine sarcoma cases who accepted treatment of beacizumab combining chemotherapy in our hospital from May 2006 to May 2014. Analyze the chemotherapy response rate (CR+RR), clinical benefit rate（CR+PR+SD）, progression-free survival (PFS) and overall survival (OR), and evaluate the safety and toxicity reaction. Results: Of four patients, 1 case achieved CR, disease-free survival time for 96 months; 1 case to PR, progression-free surial for 13 months, overall survival time for 25 months; 1 cases arrived in SD, progression-free surial for 9 months, overall survival time for 24 months, and 1 for PD, progression-free surial for3 months and overall survival time for 9 months. And the response rate (CR+RR) is 50%, clinical benefit rate（CR+PR+SD）is 75%. Treatment-related adverse reaction happened in 4 patients were bone marrow suppression and gastrointestinal reaction. 1 Of 4 cases was IV degree bone marrow suppression(PLT), others were II degree bone marrow suppression(WBC); and 2 of 4 cases were II degree gastrointestinal reaction, others were I degree gastrointestinal reaction. Conclusion: BEV combining chemotherapy can effectively control the late advanced or refractory uterine sarcoma, and well tolerated, and is expected to be a safe and effective candidate treatment of advanced recurrent or refractory uterine sarcoma.